570 related articles for article (PubMed ID: 28441138)
41. Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors.
Rajani KR; Vile RG
Viruses; 2015 Nov; 7(11):5889-901. PubMed ID: 26580645
[TBL] [Abstract][Full Text] [Related]
42. Oncolytic Adenovirus: Strategies and Insights for Vector Design and Immuno-Oncolytic Applications.
Uusi-Kerttula H; Hulin-Curtis S; Davies J; Parker AL
Viruses; 2015 Nov; 7(11):6009-42. PubMed ID: 26610547
[TBL] [Abstract][Full Text] [Related]
43. Oncolytic viruses from the perspective of the immune system.
Alemany R; Cascallo M
Future Microbiol; 2009 Jun; 4(5):527-36. PubMed ID: 19492964
[TBL] [Abstract][Full Text] [Related]
44. Cancer scene investigation: how a cold virus became a tumor killer.
Post DE; Shim H; Toussaint-Smith E; Van Meir EG
Future Oncol; 2005 Apr; 1(2):247-58. PubMed ID: 16555996
[TBL] [Abstract][Full Text] [Related]
45. Viruses - seeking and destroying the tumor program.
O'Shea CC
Oncogene; 2005 Nov; 24(52):7640-55. PubMed ID: 16299526
[TBL] [Abstract][Full Text] [Related]
46. Crosstalk between oncolytic viruses and autophagy in cancer therapy.
Jin KT; Tao XH; Fan YB; Wang SB
Biomed Pharmacother; 2021 Feb; 134():110932. PubMed ID: 33370632
[TBL] [Abstract][Full Text] [Related]
47. The use of immunohistochemistry to determine oncolytic reovirus distribution and replication in-human tumors.
Kapadia R; Coffey MC
Methods; 2010 Dec; 52(4):301-6. PubMed ID: 20801221
[TBL] [Abstract][Full Text] [Related]
48. Measles to the Rescue: A Review of Oncolytic Measles Virus.
Aref S; Bailey K; Fielding A
Viruses; 2016 Oct; 8(10):. PubMed ID: 27782084
[TBL] [Abstract][Full Text] [Related]
49. Enhanced therapeutic effect using sequential administration of antigenically distinct oncolytic viruses expressing oncostatin M in a Syrian hamster orthotopic pancreatic cancer model.
Nistal-Villan E; Bunuales M; Poutou J; Gonzalez-Aparicio M; Bravo-Perez C; Quetglas JI; Carte B; Gonzalez-Aseguinolaza G; Prieto J; Larrea E; Hernandez-Alcoceba R
Mol Cancer; 2015 Dec; 14():210. PubMed ID: 26671477
[TBL] [Abstract][Full Text] [Related]
50. Combining oncolytic virotherapy and cytotoxic therapies to fight cancer.
Fillat C; Maliandi MV; Mato-Berciano A; Alemany R
Curr Pharm Des; 2014; 20(42):6513-21. PubMed ID: 25341928
[TBL] [Abstract][Full Text] [Related]
51. Novel oncolytic viruses: riding high on the next wave?
Stanford MM; Bell JC; Vähä-Koskela MJ
Cytokine Growth Factor Rev; 2010; 21(2-3):177-83. PubMed ID: 20219409
[TBL] [Abstract][Full Text] [Related]
52. Oncolytic Viruses: The Best is Yet to Come.
Lemay CG; Keller BA; Edge RE; Abei M; Bell JC
Curr Cancer Drug Targets; 2018; 18(2):109-123. PubMed ID: 28176648
[TBL] [Abstract][Full Text] [Related]
53. [Oncolytic virotherapy: new strategies in oncology].
Fábián Z
Orv Hetil; 2007 Oct; 148(43):2019-26. PubMed ID: 17947194
[TBL] [Abstract][Full Text] [Related]
54. pH-sensitive oncolytic adenovirus hybrid targeting acidic tumor microenvironment and angiogenesis.
Choi JW; Jung SJ; Kasala D; Hwang JK; Hu J; Bae YH; Yun CO
J Control Release; 2015 May; 205():134-43. PubMed ID: 25575865
[TBL] [Abstract][Full Text] [Related]
55. [Vesicular stomatitis virus in the fight against cancer].
Janelle V; Poliquin L; Lamarre A
Med Sci (Paris); 2013 Feb; 29(2):175-82. PubMed ID: 23452604
[TBL] [Abstract][Full Text] [Related]
56. Oncolytic virotherapy for cancer treatment: challenges and solutions.
Davis JJ; Fang B
J Gene Med; 2005 Nov; 7(11):1380-9. PubMed ID: 16025557
[TBL] [Abstract][Full Text] [Related]
57. ReVOLT: radiation-enhanced viral oncolytic therapy.
Advani SJ; Mezhir JJ; Roizman B; Weichselbaum RR
Int J Radiat Oncol Biol Phys; 2006 Nov; 66(3):637-46. PubMed ID: 17011442
[TBL] [Abstract][Full Text] [Related]
58. Advance in herpes simplex viruses for cancer therapy.
Liu S; Dai M; You L; Zhao Y
Sci China Life Sci; 2013 Apr; 56(4):298-305. PubMed ID: 23564184
[TBL] [Abstract][Full Text] [Related]
59. RNA viruses as virotherapy agents.
Russell SJ
Cancer Gene Ther; 2002 Dec; 9(12):961-6. PubMed ID: 12522435
[TBL] [Abstract][Full Text] [Related]
60. Mounting a strategic offense: fighting tumor vasculature with oncolytic viruses.
Angarita FA; Acuna SA; Ottolino-Perry K; Zerhouni S; McCart JA
Trends Mol Med; 2013 Jun; 19(6):378-92. PubMed ID: 23540715
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
